Translational Genomics Research Institute

June 26, 2022, marked the 20th anniversary of tgen's launch. what began with temporary laboratory and administrative space and a handful of employees has grown into an institute with over 350 employees, multiple locations, hundreds of collaborations around the world, numerous groundbreaking studies, and nearly 20 spin-out companies. today, our capacity to understand and leverage information from the human genome has never been greater. tgen's ability to bring emerging new methods for interrogating a patient's genome into the clinical care of patients, the revolution in faster and lower-cost ways of cancer detection and the paths that reach the urban, the rural and more diverse populations, has never been greater. the sequence cost per-patient over the past decade has dropped 100-fold. this means tgen can sequence more patients, or sequence a patient again, to understand how their disease is progressing. as part of a national health system, this helps drive research discovery, new methods for early detection, and more clinical trials. sequencing accuracy has also improved 100-fold. this increased accuracy means tgen can detect cancer earlier - perhaps in its infancy - which leads to improved screening, post-treatment monitoring and biopsies with a low percentage of tumor present. this also allows us to expand genomic testing into more cancer types. we're also creating better reference genomes, especially in underserved populations. having better references means a better understanding of which changes in the genome are significant and to which population.